Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molibresib in Relapsed/Refractory Hematologic Malignancies
NCT01943851Phase 2Completed
- Sponsor
- GSK
- Start
- May 2014
- Primary completion
- Apr 2020
- Modality
- Allosteric Modulators
- Countries
- 5
01
Overview
Phase 2, open-label trial of molibresib in acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), multiple myeloma (MM) and 2 more (3 arms), sponsored by GSK. Primary endpoints: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) and AE Leading to Discontinuation (AELD) up to 86.9 weeks, Number of Participants With Dose Limiting Toxicities (DLTs) up to 3 weeks and 2 more. Started May 2014; status: completed.
02
Drugs
molibresib
03
Conditions
acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)multiple myeloma (MM)myelodysplastic syndrome (MDS)cutaneous T-cell lymphoma (CTCL)
Beyond the preview
Go deeper on NCT01943851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01943851.